Erlotinib
Most of the signal in the literature emanates from Japan (e.g. PMID 22610257). Reviews at PMID 20016372, 24332320. Recurrence may not lead to relapse (PMID 25550194), thus challenging causality
Back
The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
I - Interstitial/parenchymal lung disease
I.a
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.b
Pneumonitis (interstitial lung disease/ILD)
I.d
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g
Pulmonary fibrosis
I.l
Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.w
Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.ad
Radiation recall pneumonitis